Sorafenib Combined with Cryoablation to Treat Unresectable Hepatocellular Carcinoma

OBJECTIVE: To evaluate the efficacy and tolerability of sorafenib combined with cryoablation in treating unresectable hepatocellular carcinoma (HCC). METHODS: Patients with unresectable advanced HCC received cryoablation and sorafenib at a dose of 400 mg twice daily in 4-week cycles on the same day...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Hong, Yang, Mao, Guo, Zhi, Zhang, Ti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag Berlin Heidelberg 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587556/
https://www.ncbi.nlm.nih.gov/pubmed/23467380
http://dx.doi.org/10.1007/s11670-011-0188-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587556/
https://www.ncbi.nlm.nih.gov/pubmed/23467380
http://dx.doi.org/10.1007/s11670-011-0188-y

Ejemplares similares